Acceptability of a safer injection facility among injection drug users in San Francisco

Drug and Alcohol Dependence

Volumn 110, Issue 1-2, 2010, Pages 160-163

  Kral, Alex H ^a,b   Wenger, Lynn ^a   Carpenter, Lisa ^a   Wood, Evan ^c,d   Kerr, Thomas ^c,d   Bourgois, Philippe ^e  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST PAUL S HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acceptability; Epidemiology; HIV; IDU; Policy; Safer injection facility

Indexed keywords

ADULT; ARTICLE; DRUG ABUSE; FEMALE; HEALTH CARE FACILITY; HEALTH HAZARD; HEALTH PROGRAM; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; POLICY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK REDUCTION; SAMPLING; UNITED STATES;

ADULT; ATTITUDE; DATA COLLECTION; FEMALE; HOMELESS PERSONS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PUBLIC HEALTH; SAFETY; SAN FRANCISCO; SUBSTANCE ABUSE, INTRAVENOUS; VIDEO RECORDING;

EID: 77953704027     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.02.009     Document Type: Article

References (38)

1. Alter M.J. Epidemiology of hepatitis C. Hepatology 1997, 26:62S-65S.
2. Anoro M., llundain E., Santisteban O. Barcelona's safer injection facility-Eva: a harm reduction program lacking official support. Journal of Drug Issues 2003, 33:689-710.
3. Binswanger I.A., Kral A.H., Bluthenthal R.N., Rybold D.J., Edlin B.R. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clinical Infectious Diseases 2000, 30:579-581.
4. Bluthenthal R.N., Watters J.K. Multimethod research from targeted sampling to HIV risk environments. NIDA Research Monograph 1995, 157:212-230.
5. Bluthenthal R.N., Do D.P., Finch B., Martinez A.N., Edlin B.R., Kral A.H. Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis. Journal of Urban Health 2007, 84(5):653-666.
6. Broadhead B.S., Kerr T.H., Grund J.-P.G., Altice F.L. Safer injection facilities in North America: their place in public policy and health initiatives. Journal of Drug Issues 2002, 32:329-355.
7. Coffin P.O., Galea S., Ahern J., Leon A.C., Vlahov D., Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-1998. Addiction 2003, 98:739-747.
8. Des Jarlais D., Friedman S.W.H. Risk reduction for the acquired immune deficiency syndrome among intravenous drug users. Annals of Internal Medicine 1985, 103:755-759.
9. Dolan K., Kimber J., Fry C., Fitzgerald J., McDonald D., Trautmann F. Drug consumption facilities in Europe and the establishment of supervised injecting centers in Australia. Drug and Alcohol Review 2000, 19:337-346.
10. Drug Policy Alliance Preventing Overdose, Saving Lives: Strategies for Combating a National Crisis 2009, Drug Policy Alliance, New York.
11. Fast D., Small W., Wood E., Kerr T. The perspectives of injection drug users regarding safer injecting education delivered through a supervised injecting facility. Harm Reduction Journal 2008, 5:32.
12. Fry C. Injecting drug users attitudes towards rules for supervised injecting rooms: implications for uptake. The International Journal of Drug Policy 2002, 13.
13. Hedrich, D., Kerr, T., Dubois-Arber, F., in press. Drug consumption facilities and beyond. In: Rhodes, T. (Eds.), Harm Reduction: Evidence, Impacts and Challenges. European Monitoring Centre for Drugs and Drug Addiction, Office for Official Publications of the European Communities, Luxembourg.
14. Hunt, N., 2006. An overview of models of delivery of drug consumption rooms. The Report of the Independent Working Group on Drug Consumption Rooms. Joseph Rowntree Foundation, York.
15. Kerr T., Small W., Moore D., Wood E. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility. The International Journal of Drug Policy 2007, 18:37-45.
16. Kerr T., Tyndall M., Li K., Montaner J., Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005, 366:316-318.
17. Kerr T., Wood E., Small D., Palepu A., Tyndall M.W. Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside. CMAJ 2003, 169:759-763.
18. Kimber J., Dolan K., Wodak A. Survey of drug consumption rooms: service delivery and perceived public health and amenity impact. Drug and Alcohol Review 2005, 24:21-24.
19. Kral A.H., Bluthenthal R.N., Lorvick J., Gee L., Bacchetti P., Edlin B.R. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001, 357:1397-1401.
20. Latkin C., Mandell W., Vlahov D., Oziemkowska M., Knowlton A., Celentano D. My place, your place, and no place: behavior settings as a risk factor for HIV-related injection practices of drug users in Baltimore, Maryland. American Journal of Community Psychology 1994, 22:415-430.
21. Lorvick J., Kral A.H., Seal K., Gee L., Edlin B.R. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. American Journal of Public Health 2001, 91:46-47.
22. McFarland W. Proposed 2006 HIV Consensus Estimates. HIV Prevention Planning Council: 2006 Full Council Meeting 2006, San Francisco Department of Public Health, San Francisco.
23. Milloy M.J., Kerr T., Tyndall M., Montaner J., Wood E. Estimated drug overdose deaths averted by North America's first medically supervised safer injection facility. PLos ONE 2008, 3:e3351.
24. Petrar S., Kerr T., Tyndall M.W., Zhang R., Montaner J.S., Wood E. Injection drug users' perceptions regarding use of a medically supervised safer injecting facility. Addictive Behaviors 2007, 32:1088-1093.
25. Reynolds A. A global overview of safe injection facilities: key policies and practices. Safe Injection Facilities Symposium 2007.
26. Rhodes T., Kimber J., Small W., Fitzgerald J., Kerr T., Hickman M., Holloway G. Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction 2006, 101:1384-1393.
27. SAS Institute Inc. SAS Release 9. 13 Service Pack 4 2002-2003, SAS Institute Inc., Cary, N.C.
28. Sherman S.G., Cheng Y., Kral A.H. Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. city. Drug and Alcohol Dependence 2007, 88:182-187.
29. Tseng F.C., Edlin B.R., Zhang M., Kral A.H., Busch M.P., Ortiz-Conde B.A., Welzel T.M., O'Brien T.R. The inverse relationship between chronic HBV and HCV infections among injection drug users associated with decades of age and drug use. Journal of Viral Hepatitis 2008, 15:690-698.
30. Tyndall M.W., Kerr T., Zhang R., King E., Montaner J.G., Wood E. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug and Alcohol Dependence 2006, 83:193-198.
31. van den Hoek J.A., Coutinho R.A., van Haastrecht H.J., van Zadelhoff A.W., Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988, 2:55-60.
32. Vlahov D., Fuller C.M., Ompad D.C., Galea S., Des Jarlais D.C. Updating the infection risk reduction hierarchy: preventing transition into injection. Journal of Urban Health 2004, 81:14-19.
33. Watters J.K., Biernacki P. Targeted sampling: options for the study of hidden populations. Social Problems 1989, 36:416-430.
34. Westat Blaise 4. 0 2009, Westat, Rockville, MD.
35. Wood E., Kerr T., Montaner J.S., Strathdee S.A., Wodak A., Hankins C.A., Schechter M.T., Tyndall M.W. Rationale for evaluating North America's first medically supervised safer-injecting facility. The Lancet Infectious Diseases 2004, 4:301-306.
36. Wood E., Kerr T., Small W., Li K., Marsh D.C., Montaner J.S., Tyndall M.W. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ 2004, 171:731-734.
37. Wood E., Tyndall M.W., Qui Z., Zhang R., Montaner J.S., Kerr T. Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility. American Journal of Public Health 2006, 96:770-773.
38. Wood E., Tyndall M.W., Zhang R., Montaner J.S., Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction 2007, 102:916-919.